Neutropenia During HIV Infection: Adverse Consequences and Remedies

Overview

Journal Int Rev Immunol

Publisher Informa Healthcare

Specialty Allergy & Immunology

Date 2014 Mar 25

PMID 24654626

Citations 34

Authors

Xin Shi

Matthew D Sims

Michel M Hanna

Ming Xie

Peter G Gulick

Yong-Hui Zheng

Marc D Basson

Ping Zhang

Affiliations

Soon will be listed here.

Abstract

Neutropenia frequently occurs in patients with Human immunodeficiency virus (HIV) infection. Causes for neutropenia during HIV infection are multifactoral, including the viral toxicity to hematopoietic tissue, the use of myelotoxic agents for treatment, complication with secondary infections and malignancies, as well as the patient's association with confounding factors which impair myelopoiesis. An increased prevalence and severity of neutropenia is commonly seen in advanced stages of HIV disease. Decline of neutrophil phagocytic defense in combination with the failure of adaptive immunity renders the host highly susceptible to developing fatal secondary infections. Neutropenia and myelosuppression also restrict the use of many antimicrobial agents for treatment of infections caused by HIV and opportunistic pathogens. In recent years, HIV infection has increasingly become a chronic disease because of progress in antiretroviral therapy (ART). Prevention and treatment of severe neutropenia becomes critical for improving the survival of HIV-infected patients.

Citing Articles

Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia.

Gudina A, Wordofa M, Urgessa F PLoS One. 2024; 19(10):e0310239.

PMID: 39480901 PMC: 11527299. DOI: 10.1371/journal.pone.0310239.

Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study.

Brittain D, Akhtar S, Rodrigues S, Patel M, Moodley D, Singh J Turk J Haematol. 2024; 41(4):211-224.

PMID: 39463021 PMC: 11628755. DOI: 10.4274/tjh.galenos.2024.2024.0181.

Role of Type I Interferons during and HIV Infections.

Anes E, Azevedo-Pereira J, Pires D Biomolecules. 2024; 14(7).

PMID: 39062562 PMC: 11275242. DOI: 10.3390/biom14070848.

Causes and outcomes of non-chemotherapy induced neutropenic fever in hospitalized adults: An observational study.

Crooker K, Stedman E, Hitt J, Tompkins B, Repp A Medicine (Baltimore). 2024; 103(18):e38060.

PMID: 38701281 PMC: 11062702. DOI: 10.1097/MD.0000000000038060.

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV.

Motta E, Camacho L, Cunha M, de Filippis A, Lima S, Costa M AIDS. 2023; 37(15):2319-2329.

PMID: 37650759 PMC: 10653289. DOI: 10.1097/QAD.0000000000003696.

References

Chen T, Wong W, Chiou T . Hemophagocytic syndrome: an unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol. 2004; 78(5):450-2. DOI: 10.1007/BF02983819. View

Isgro A, Aiuti A, Mezzaroma I, Addesso M, Riva E, Giovannetti A . Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy. Br J Haematol. 2002; 118(3):864-74. DOI: 10.1046/j.1365-2141.2002.03680.x. View

Katsarou O, Terpos E, Patsouris E, Peristeris P, Viniou N, Kapsimali V . Myelodysplastic features in patients with long-term HIV infection and haemophilia. Haemophilia. 2001; 7(1):47-52. DOI: 10.1046/j.1365-2516.2001.00445.x. View

Morad V, Pevsner-Fischer M, Barnees S, Samokovlisky A, Rousso-Noori L, Rosenfeld R . The myelopoietic supportive capacity of mesenchymal stromal cells is uncoupled from multipotency and is influenced by lineage determination and interference with glycosylation. Stem Cells. 2008; 26(9):2275-86. DOI: 10.1634/stemcells.2007-0518. View

Mondy K, Tebas P . Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(Suppl 2):S101-5. DOI: 10.1086/367566. View

Wang L, Mondal D, La Russa V, Agrawal K . Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type 1 tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses. 2002; 18(13):917-31. DOI: 10.1089/088922202760265597. View

Spivak J, Selonick S, Quinn T . Acquired immune deficiency syndrome and pancytopenia. JAMA. 1983; 250(22):3084-7. View

Schwartz G, Kessler S, Rothwell S, Burrell L, Reid T, Meltzer M . Inhibitory effects of HIV-1-infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures. Exp Hematol. 1994; 22(13):1288-96. View

Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M . Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med. 2001; 40(8):795-801. DOI: 10.2169/internalmedicine.40.795. View

10.

Clark R, Blakley S, Greer D, Smith M, Brandon W, Wisniewski T . Hematogenous dissemination of Mycobacterium tuberculosis in patients with AIDS. Rev Infect Dis. 1991; 13(6):1089-92. DOI: 10.1093/clinids/13.6.1089. View

11.

Imperia P, Chikkappa G, Phillips P . Mechanism of inhibition of granulopoiesis by ethanol. Proc Soc Exp Biol Med. 1984; 175(2):219-25. DOI: 10.3181/00379727-175-41792. View

12.

Prakash O, Zhang P, Xie M, Ali M, Zhou P, Coleman R . The human immunodeficiency virus type I Tat protein potentiates ethanol-induced neutrophil functional impairment in transgenic mice. Alcohol Clin Exp Res. 1999; 22(9):2043-9. View

13.

Moore D, Benepal T, Portsmouth S, Gill J, Gazzard B . Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis. 2001; 32(3):469-75. DOI: 10.1086/318495. View

14.

Kuritzkes D, Parenti D, WARD D, Rachlis A, Wong R, Mallon K . Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS. 1998; 12(1):65-74. DOI: 10.1097/00002030-199801000-00008. View

15.

Zeldis J, Mugishima H, Steinberg H, Nir E, Gale R . In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest. 1986; 78(2):411-7. PMC: 423568. DOI: 10.1172/JCI112591. View

16.

Choi S, Kim I, Kim N, Lee S, Choi Y, Bae J . Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia. Korean J Hematol. 2012; 46(4):253-7. PMC: 3259517. DOI: 10.5045/kjh.2011.46.4.253. View

17.

Scadden D, Wang A, Zsebo K, Groopman J . In vitro effects of stem-cell factor or interleukin-3 on myelosuppression associated with AIDS. AIDS. 1994; 8(2):193-6. DOI: 10.1097/00002030-199402000-00006. View

18.

Zon L, Arkin C, Groopman J . Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol. 1987; 66(2):251-6. DOI: 10.1111/j.1365-2141.1987.tb01307.x. View

19.

Burke M, Yust I, Katlama C, VARDINON N, Clumeck N, Pinching A . Cytomegalovirus retinitis in patients with AIDS in Europe. AIDS in Europe Study Group. Eur J Clin Microbiol Infect Dis. 1998; 16(12):876-82. DOI: 10.1007/BF01700553. View

20.

Meira D, Lorand-Metze I, Toro A, Silva M, Vilela M . Bone marrow features in children with HIV infection and peripheral blood cytopenias. J Trop Pediatr. 2005; 51(2):114-9. DOI: 10.1093/tropej/fmh096. View